Pharmacological read-through of nonsense ARSB mutations as a potential therapeutic approach for mucopolysaccharidosis VI

38Citations
Citations of this article
54Readers
Mendeley users who have this article in their library.

Abstract

Mucopolysaccharidosis type VI (MPS VI) is a severe lysosomal storage disorder without central nervous system involvement caused by arylsulfatase B (ARSB) deficiency. MPS VI is characterized by dysostosis multiplex, corneal clouding, heart valve defects and urinary excretion of glycosaminoglycans (GAGs). The current treatment for MPS VI is enzyme replacement therapy (ERT) which has limited efficacy on bone, joints and heart valve disease, as well as high costs. A potential therapeutic approach for the subgroup of MPS VI patients that carry nonsense mutations is to enhance stop-codon read-through, using small molecules, to restore production of the full-length ARSB protein. In this study we investigated whether two compounds known to induce stop codon read-through, the aminoglycoside gentamicin and PTC124, can promote read-through of four different ARSB nonsense mutations (p.R315X, p.R327X, p.Q456X and p.Q503X) associated with MPS VI and enable the synthesis of full-length functional ARSB protein in patients fibroblast cell lines. Our study demonstrates that PTC124 but not gentamicin, increases the level of ARSB activity in three MPS VI patient fibroblast cell lines. In two of them the levels of ARSB activity obtained were significantly higher than in untreated cells, reaching ≤2.5 % of those detected in wild-type fibroblasts and resulting in significant reduction of lysosomal size. Since even small increases in enzyme activity can dramatically influence the clinical phenotype of MPS VI, our study suggests that pharmacological read-through may be combined with ERT potentially increasing therapeutic efficacy in those patients bearing nonsense ARSB mutations. © 2012 The Author(s).

References Powered by Scopus

PTC124 targets genetic disorders caused by nonsense mutations

956Citations
N/AReaders
Get full text

A rule for termination-codon position within intron-containing genes: When nonsense affects RNA abundance

954Citations
N/AReaders
Get full text

Aminoglycoside antibiotics mediate context-dependent suppression of termination codons in a mammalian translation system

322Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Ataluren treatment of patients with nonsense mutation dystrophinopathy

354Citations
N/AReaders
Get full text

Therapeutics based on stop codon readthrough

229Citations
N/AReaders
Get full text

Nonsense-mediated decay in genetic disease: Friend or foe?

159Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Bartolomeo, R., Polishchuk, E. V., Volpi, N., Polishchuk, R. S., & Auricchio, A. (2013). Pharmacological read-through of nonsense ARSB mutations as a potential therapeutic approach for mucopolysaccharidosis VI. Journal of Inherited Metabolic Disease, 36(2), 363–371. https://doi.org/10.1007/s10545-012-9521-y

Readers over time

‘12‘13‘14‘15‘16‘17‘18‘19‘20‘21‘22‘23‘24‘25036912

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 20

57%

Researcher 12

34%

Professor / Associate Prof. 2

6%

Lecturer / Post doc 1

3%

Readers' Discipline

Tooltip

Agricultural and Biological Sciences 11

35%

Biochemistry, Genetics and Molecular Bi... 9

29%

Medicine and Dentistry 8

26%

Chemistry 3

10%

Save time finding and organizing research with Mendeley

Sign up for free
0